Combination therapy for cough and bronchial obstruction in childhood

Abstract

The inflammatory process in the bronchial mucosa of various origins (infectious, allergic, irritative, etc.) cause changes in the sputum production and its rheological properties, slowing of mucociliary clearance. Mucoactive therapy is one of the important components of the management of bronchopulmonary diseases. The article provides a detailed review of the modern literature, as well as the authors’ own experience regarding the cough therapy methods, including techniques used in the bronchial obstructive syndrome. The use of combination drugs, which simultaneously affect various pathogenetic mechanisms of inflammation and cough, including those in the respiratory diseases with bronchial obstructive syndrome, becomes a promising direction of mucoactive therapy. Due to relative safety and clinical efficacy, the modern combination therapy, including a fixed-dose combination of salbutamol, bromhexine, guaifenesin (Ascoril, Ascoril expectorant), is increasingly becoming the drug of informed choice in mild bronchial obstruction in childhood in pediatric practice.

Keywords

• children
• cough
• bronchial obstructive syndrome
• mucolytic therapy
• combination drugs
• ascoril®
• ascoril expectorant®